End-to-end laser drilling for osmotic controlled-release tablets — pairing the Olando K3-2 system with vision QC, dust extraction, and GMP/MES integration.
Our laser drilling solution enables precise apertures (typ. sub-millimeter) for osmotic tablets to achieve stable release profiles. The solution can run stand-alone or be integrated inline, and supports GMP cleanroom operation with electronic record features and MES connectivity.
Core Modules
Olando K3-2 Laser Drilling System (configurable for single/dual apertures).
Vision inspection for aperture presence/diameter/positioning; reject handling.
Dust extraction & tablet handling designed for cleanroom environments.
Batch management with optional MES/ERP interface and e-records support.
Validation documentation and operator/maintenance training services.
Client Case Studies
Client Case 1 — Shanghai Modern Pharmaceutical Co., Ltd.
Shanghai Modern Pharmaceutical has been a key user of our laser drilling technology for nearly 20 years. Starting from the first-generation Olando systems, they have continuously upgraded with our latest models, including the K3 series. To date, they have purchased and deployed a total of 12 Olando laser drilling machines in their production facilities.
Product Application
Nifedipine Controlled-Release Tablets (CR) — requiring precise laser-drilled apertures to control osmotic release over an extended period, ensuring consistent therapeutic effects.
GMP Compliance & Performance
All equipment is operated in full GMP-compliant cleanroom environments.
Systems have demonstrated high precision, stable throughput, and strong reliability under daily industrial-scale production.
Long-term cooperation and repeated purchases underscore proven performance and after-sales support quality.
Workshop and product photos:
Client Case 2 — Shanghai Xinyi Pharmaceutical Co., Ltd.
Company: Shanghai Xinyi Pharmaceutical Co., Ltd.
Established: 1943
Core Focus: Prescription drugs and sustained-release dosage forms
Ownership: Subsidiary of Shanghai Pharmaceutical Holding Co., Ltd. (SSE-listed)
Project Summary
In 2023, Xinyi Pharmaceutical purchased three units of our Olando K3-2 Laser Drilling System for their advanced formulation line. These machines are specifically used in the production of Doxazosin Mesylate Controlled-Release Tablets, a medication commonly used to treat hypertension and benign prostatic hyperplasia (BPH).
Q: How does laser drilling create controlled-release tablets?
A: Laser drilling creates a precise aperture (typically 0.3–1.2mm diameter) in the tablet coating, forming the drug delivery orifice for osmotic pump tablet systems (OROS technology). The osmotic pressure differential between the tablet core and gastrointestinal fluids drives API release through this aperture at a controlled rate. Hole diameter, depth (blind vs. through-hole), and position are critical parameters—variations of ±0.1mm or more can significantly alter release kinetics. The Olando K3-2 maintains ±0.1mm accuracy at 120,000 tablets/hour using closed-loop vision detection.
Q: What is the difference between blind holes and through-holes in osmotic tablets?
A: Through-holes penetrate the entire tablet coating, creating bidirectional flow. Blind holes penetrate only the tablet coat (not the core), creating a single-direction orifice. Most OROS formulations (e.g., Nifedipine CR, Doxazosin Mesylate) use a single blind hole on the coat surface, preserving core integrity while enabling precise osmotic release. Blind holes require tighter laser parameter control because the laser must stop within the coating layer—the Olando K3-2's Siemens PLC-controlled laser delivery system ensures consistent hole depth within ±0.05mm, preventing API core exposure.
Q: What tablet shapes and sizes can the Olando K3-2 process?
A: The Olando K3-2 handles round tablets (bilayer and single-layer) with adjustable feed channel geometry. Standard configurations support tablet diameters from approximately 6mm to 20mm, covering the vast majority of osmotic tablet designs for cardiovascular, CNS, and metabolic indications. The system processes 120,000 tablets/hour (single aperture configuration), equivalent to approximately 2 billion tablets annually on a standard 24/7 production schedule. Contact us with your specific tablet dimensions for configuration confirmation.
Q: Does laser drilling comply with FDA 21 CFR Part 11?
A: The Olando K3-2 Laser Drilling System is designed for cGMP environments and includes Siemens PLC-based process control with audit trail functionality—recording all parameter changes, operator interventions, and batch data in tamper-evident electronic records. This supports compliance with FDA 21 CFR Part 11 and EU Annex 11 data integrity requirements. For full Part 11 compliance, integrate the system's data outputs into a validated manufacturing execution system (MES) or LIMS. Reference customers include Shanghai Modern Pharmaceutical (12 installed units for Nifedipine CR) and Shanghai Xinyi Pharmaceutical (3 units for Doxazosin Mesylate).
Q: What are the ongoing maintenance requirements for laser drilling equipment?
A: Key maintenance items for the Olando K3-2: (1) Laser source service interval: approximately every 10,000 operating hours (roughly 14 months at 24/7 operation); (2) Vision system calibration: recommended every 3–6 months or after any process parameter change; (3) Optics cleaning: weekly inspection, cleaning as needed based on particulate environment. Preventive maintenance should be incorporated into your equipment qualification protocol (IQ/OQ/PQ). Huanghai provides remote diagnostics support and on-site service through our Singapore operations hub. Request our service agreement terms.
Contact us
Quick Access:
Pharmaceutical Testing Instruments
– Explore solutions for dissolution, hardness, and disintegration testers tailored to your pharmaceutical quality control.
Laboratory Instrument Solutions
– Customized lab setups including UV-Vis spectrophotometers, balances, and pH meters for research and QC labs.
